[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病防治指南(2018更新版). 中华肝脏病杂志, 2018, 26:195-203.
[2] Wen Y, Chen YQ, Konrad RJ. The regulation of triacylglycerol metabolism and lipoprotein lipase activity. Adv Biology, 2022,6(10):e2200093.
[3] Serra MC, Ryan AS, Goldberg AP. Reduced LPL and subcutaneous lipid storage capacity are associated with metabolic syndrome in postmenopausal women with obesity. Obes Sci Pract, 2017, 3(1):106-114.
[4] Liu N, Sang Y, Chen S, et al. Associations of the LPL S447X and hind III polymorphism with type 2 diabetes mellitus risk: a meta-analysis. Horm Metab Res, 2021, 53(1):49-55.
[5] Pardina E, Baena-Fustegueras JA, Llamas R, et al. Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis. Obes Surg, 2009, 19(5):608-616.
[6] Chang CL. Lipoprotein lipase: new roles for an ′old′ enzyme. Curr Opin Clin Nutr Metab Care, 2019, 22(2):111-115.
[7] Allan CM, Larsson M, Jung RS, et al. Mobility of “HSPG-bound” LPL explains how LPL is able to reach GPIHBP1 on capillaries. J Lipid Res, 2017, 58(1):216-225.
[8] Young SG, Fong LG, Beigneux AP, et al. GPIHBP1 and lipoprotein lipase, partners in plasma triglyceride metabolism. Cell Metab, 2019, 30(1):51-65.
[9] Young SG, Song W, Yang Y, et al. A protein of capillary endothelial cells, GPIHBP1, is crucial for plasma triglyceride metabolism. Proc Natl Acad Sci U S A, 2022, 119(36):e2211136119.
[10] Wu SA, Kersten S, Qi L. Lipoprotein lipase and its regulators: an unfolding story. Trends Endocrinol Metab, 2021, 32(1):48-61.
[11] Mehta A, Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease. Nat Rev Cardiol, 2022, 19(3):168-179.
[12] Sylvers-Davie KL, Davies BSJ. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. Am J Physiol Endocrinol Metab, 2021, 321(4):E493-E508.
[13] Beigneux AP, Allan CM, Sandoval NP, et al. Lipoprotein lipase is active as a monomer. Proc Natl Acad Sci U S A, 2019, 116(13):6319-6328.
[14] Leth-Espensen KZ, Kristensen KK, Kumari A, et al. The intrinsic instability of the hydrolase domain of lipoprotein lipase facilitates its inactivation by ANGPTL4-catalyzed unfolding. Proc Natl Acad Sci U S A, 2021, 118(12):e2026650118.
[15] Grzegorczyk EA, Harasim-Symbor E, Lukaszuk B, et al. Lack of pronounced changes in the expression of fatty acid handling proteins in adipose tissue and plasma of morbidly obese humans. Nutr Diabetes, 2018, 8(1):3.
[16] Tsankof A, Neokosmidis G, Koureta E, et al. Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease? Front Endocrinol (Lausanne), 2022, 13:984041.
[17] Nishida Y, Nishijima K, Yamada Y, et al. Whole-body insulin resistance and energy expenditure indices, serum lipids, and skeletal muscle metabolome in a state of lipoprotein lipase overexpression. Metabolomics, 2021, 17(3):26.
[18] Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet, 2017, 49(1):17-26.
[19] Geldenhuys WJ, Lin L, Darvesh AS, et al. Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases. Drug Discov Today, 2017, 22(2):352-365.
[20] Huang Y, Qin Y, Liao L, et al. Familial chylomicronemia syndrome caused by compound heterozygous mutation of lipoprotein lipase gene: a case report and review of literature. Clin Chim Acta, 2022, 537:112-117.
[21] Moon JH, Kim K, Choi SH. Lipoprotein lipase: is it a magic target for the treatment of hypertriglyceridemia. Endocrinol Metab (Seoul), 2022, 37(4):575-586.
[22] Walton RG, Zhu B, Unal R, et al. Increasing adipocyte lipoprotein lipase improves glucose metabolism in high fat diet-induced obesity. J Biol Chem, 2015, 290(18):11547-11556.
[23] Spitler KM, Shetty SK, Cushing EM, et al. Regulation of plasma triglyceride partitioning by adipose-derived ANGPTL4 in mice. Sci Rep, 2021, 11(1):7873.
[24] Ghodsian N, Abner E, Emdin CA, et al. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Rep Med, 2021, 2(11):100437.
[25] Liu G, Xu JN, Liu D, et al. Regulation of plasma lipid homeostasis by hepatic lipoprotein lipase in adult mice. J Lipid Res, 2016, 57(7):1155-1161.
[26] Teratani T, Tomita K, Furuhashi H, et al. Lipoprotein lipase up-regulation in hepatic stellate cells exacerbates liver fibrosis in nonalcoholic steatohepatitis in mice. Hepatol Commun, 2019, 3(8):1098-1112.
[27] Teratani T, Tomita K, Wada A, et al. Angiopoietin-like protein 4 deficiency augments liver fibrosis in liver diseases such as nonalcoholic steatohepatitis in mice through enhanced free cholesterol accumulation in hepatic stellate cells. Hepatol Res, 2021, 51(5):580-592.
[28] Li H, Liu G, Wan X, et al. The zinc finger and BTB domain containing protein ZBTB20 regulates plasma triglyceride metabolism by repressing lipoprotein lipase gene transcription in hepatocytes. Hepatology, 2022, 75(5):1169-1180.
[29] Shimizu K, Nishimuta S, Fukumura Y, et al. Liver-specific overexpression of lipoprotein lipase improves glucose metabolism in high-fat diet-fed mice. PLoS One, 2022, 17(9):e0274297.
[30] Fougerat A, Montagner A, Loiseau N, et al. Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease. Cells, 2020, 9(7):1638.
[31] Kawaguchi-Suzuki M, Cusi K, Bril F, et al. A genetic score associates with pioglitazone response in patients with non-alcoholic steatohepatitis. Front Pharmacol, 2018, 9:752. |
